NuCana plc Presents New ProTide Technology Data
Ticker: NCNA · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: data-presentation, biotech, cancer-therapeutics
TL;DR
NuCana dropped new data on their ProTide tech at a cancer symposium.
AI Summary
On October 18, 2025, NuCana plc announced the presentation of data from a new model system investigating the potential of its ProTide technology. This presentation occurred at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium.
Why It Matters
The presentation of new data on NuCana's ProTide technology could impact the future development and potential of their cancer therapeutics.
Risk Assessment
Risk Level: low — This filing is an informational report (6-K) about a data presentation, not a material financial event.
Key Players & Entities
- NuCana plc (company) — Registrant
- October 18, 2025 (date) — Date of press release
- 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium (event) — Symposium where data was presented
FAQ
What is the main purpose of this 6-K filing?
The main purpose is to report on NuCana plc's press release dated October 18, 2025, announcing the presentation of data on a new model system for their ProTide technology at a symposium.
When was the press release issued?
The press release was issued on October 18, 2025.
Where was the data presented?
The data was presented at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium.
What technology is NuCana plc investigating with this new model system?
NuCana plc is investigating its ProTide technology.
What is NuCana plc's principal executive office address?
NuCana plc's principal executive office is located at 3 Lochside Way, Edinburgh EH12 9DT, United Kingdom.
Filing Stats: 351 words · 1 min read · ~1 pages · Grade level 15.7 · Accepted 2025-10-20 08:00:11
Filing Documents
- d917681d6k.htm (6-K) — 10KB
- d917681dex991.htm (EX-99.1) — 13KB
- 0001193125-25-243050.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NuCana plc By: /s/ Ian Webster Name: Ian Webster Title: Interim Chief Financial Officer (Principal Financial and Accounting Officer) Date: October 20, 2025